Summary

OBJECTIVES: I. Determine the prevalence of glucocorticoid-remediable aldosteronism (GRA) invarious hypertensive populations and screen at risk members of GRA pedigrees.II. Investigate other factors regulating blood pressure in GRA (environmental, geneticallydetermined factors).III. Investigate renal and hormonal mechanisms regulating potassium homeostasis in GRA.IV. Describe clinical phenotype of GRA patients. V. Prospectively screen GRA-affectedpatients with MRI angiography for intracranial aneurysm.

Study Name: Study of Prevalence and Clinical Phenotype in Patients With Glucocorticoid-Remediable Aldosteronism
Status: Completed
Conditions: Primary aldosteronism
Interventions: Observational only
Locations: Brigham and Women’s Hospital, Boston, Massachusetts, United States
Study link: https://ClinicalTrials.gov/show/NCT00004354

To search for other studies by topic, location, or status, go to our Clinical Studies page.

©2021 Primary Aldosteronism Foundation — All Rights Reserved

The Primary Aldosteronism Foundation is a registered 501(c)(3) public charity. Donations are tax deductible in the US.

©2021 Primary Aldosteronism Foundation

The Primary Aldosteronism Foundation is a registered 501(c)(3) public charity. Donations are tax deductible in the US.